A Phase I/II Study of Quizartinib in Combination With Decitabine for the Treatment of Patients With Acute Myeloid Leukemia (AML)
Phase of Trial: Phase I/II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Decitabine (Primary) ; Quizartinib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 15 Aug 2019 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.
- 15 Aug 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.
- 15 Aug 2019 Venetoclax drug has been added in the trial, hence the protocol was amended.